Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [2]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [2]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [2]. Group 2: Lead Plaintiff Process - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [3]. - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3]. Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand [5][6]. - The company disclosed on August 4, 2025, that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. Stock Performance - Following the announcement of the delayed launch, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the safety and performance of its Novum LVP device, which has been linked to serious patient risks and malfunctions [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP that led to malfunctions such as underinfusion and overinfusion, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths associated with the Novum LVP but did not take adequate remedial measures [2]. - The company issued warnings to customers about the risks but continued to face issues with the device, leading to a temporary halt in shipments and installations [3]. Group 2: Financial Impact - Following the announcement of safety concerns and the decision to pause shipments, Baxter's stock price fell by $6.29, approximately 22.4%, from $28.05 to $21.76 on July 31, 2025 [3].

Core Viewpoint - Rosen Law Firm is reminding investors of Inspire Medical Systems, Inc. to secure counsel before the January 5, 2026 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 5, 2026 [3][5]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - Femasys Inc. has achieved significant regulatory milestones, including FDA IDE approval for the final pivotal trial of FemBloc, which positions the company for potential U.S. FDA approval [3][5][19] - The company secured $12 million in financing, enhancing its balance sheet and extending its cash runway, with total potential funding of $58 million if all warrants are exercised [5][7] - Sales for the third quarter of 2025 increased by 31.4% to $729,394, driven primarily by FemBloc sales, while R&D expenses decreased significantly [6][12] Regulatory Approvals - Femasys received regulatory approvals for the complete FemBloc System in the U.K. and New Zealand, expanding access to this non-surgical permanent birth control option [3][5][19] - Initial commercial orders have been received from distribution partners in Spain and France, indicating early momentum in the European market [3][5] Financial Performance - For the third quarter of 2025, sales increased by $174,486 to $729,394 compared to the same period in 2024, primarily due to FemBloc [6] - R&D expenses decreased by 40.0% to $1,382,022, reflecting a shift towards commercialization and reduced costs [6] - The net loss for the third quarter was $4,194,821, or ($0.10) per share, an improvement from a net loss of $5,408,860, or ($0.24) per share, in the prior year [6] Cash Position - As of September 30, 2025, Femasys had approximately $4.6 million in cash and cash equivalents, with an accumulated deficit of approximately $141.9 million [7] - The company expects its current cash position, bolstered by recent financing, to fund operations into September 2026 [7] Strategic Partnerships - Femasys announced a partnership with Kebomed to commercialize FemBloc in France and the Benelux region, enhancing its distribution capabilities [5] - A partnership with Medical Electronic Systems LLC was established to provide the FemSperm™ Analysis Kit, further expanding the company's product offerings [5]

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without approval from the U.S. Food and Drug Administration [2]. - It is alleged that these design changes compromised the reliability of the G6 and G7 devices, posing a significant health risk to users who depend on accurate glucose readings [2]. - The complaint asserts that the enhancements claimed for the G7, including its reliability, accuracy, and functionality, were overstated by the defendants [2]. - Defendants are accused of downplaying the severity of the issues and health risks associated with the altered G7 devices [2]. - The lawsuit suggests that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - As a result, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses in DexCom, Inc. during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged securities fraud affecting shareholders between August 6, 2024, and August 4, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that the company made false statements regarding the launch of its new product, Inspire V, which was reportedly unsuccessful due to poor demand and excess inventory at treatment centers [3]. - Allegations include that Inspire Medical Systems failed to complete essential tasks for a successful product launch, such as training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Insights - Retractable Technologies, Inc. has received an Innovative Technology designation from Vizient for its EasyPoint® Blood Collection Tube Holder with Needle, highlighting its potential to enhance patient care and safety in healthcare settings [1][2][4] Product Innovation - The EasyPoint Blood Collection Tube Holder (BCTH) features automated retraction for instant safety, reducing exposure to contaminated needles and minimizing the risk of needlestick injuries [3] - The device is designed for ease of use, with a pre-attached needle that eliminates assembly time, improving workflow efficiency and inventory management [3] - The integrated safety mechanism allows for optimal visibility of the venipuncture site, promoting successful first-attempt procedures [3] - The product's unique off-line retraction can be activated with one hand, reducing patient discomfort and ensuring compliance with safety regulations by rendering the device non-reusable after activation [3] Company Commitment - The CEO of Retractable Technologies, Inc. expressed pride in the recognition from Vizient, emphasizing the company's mission to enhance safety and reliability in healthcare through innovative engineering [4] - Vizient's associate vice president acknowledged the EasyPoint device's potential impact on the healthcare industry, reinforcing the importance of such innovations [4] Company Overview - Retractable Technologies, Inc. manufactures safety medical products, including VanishPoint and Patient Safe syringes, aimed at preventing needlestick injuries and reducing the risk of bloodstream infections [5] - The company's products are distributed through various specialty and general line distributors, indicating a broad market reach [6]